EP3242671A4 - Ex vivo-verfahren zur minimierung der risiken und maximierung der vorteile von allogener blut- und knochenmarktransplantation - Google Patents

Ex vivo-verfahren zur minimierung der risiken und maximierung der vorteile von allogener blut- und knochenmarktransplantation Download PDF

Info

Publication number
EP3242671A4
EP3242671A4 EP16735447.1A EP16735447A EP3242671A4 EP 3242671 A4 EP3242671 A4 EP 3242671A4 EP 16735447 A EP16735447 A EP 16735447A EP 3242671 A4 EP3242671 A4 EP 3242671A4
Authority
EP
European Patent Office
Prior art keywords
marrow transplantation
vivo methods
allogeneic blood
minimizing risks
maximizing benefits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16735447.1A
Other languages
English (en)
French (fr)
Other versions
EP3242671A1 (de
Inventor
Jenny Zilberberg
Woo Lee
Robert Korngold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stevens Institute of Technology
Hackensack University Medical Center
Original Assignee
Hackensack University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hackensack University Medical Center filed Critical Hackensack University Medical Center
Publication of EP3242671A1 publication Critical patent/EP3242671A1/de
Publication of EP3242671A4 publication Critical patent/EP3242671A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP16735447.1A 2015-01-08 2016-01-08 Ex vivo-verfahren zur minimierung der risiken und maximierung der vorteile von allogener blut- und knochenmarktransplantation Withdrawn EP3242671A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101181P 2015-01-08 2015-01-08
PCT/US2016/012573 WO2016112245A1 (en) 2015-01-08 2016-01-08 Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation

Publications (2)

Publication Number Publication Date
EP3242671A1 EP3242671A1 (de) 2017-11-15
EP3242671A4 true EP3242671A4 (de) 2018-08-08

Family

ID=56356448

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16735447.1A Withdrawn EP3242671A4 (de) 2015-01-08 2016-01-08 Ex vivo-verfahren zur minimierung der risiken und maximierung der vorteile von allogener blut- und knochenmarktransplantation

Country Status (3)

Country Link
EP (1) EP3242671A4 (de)
CA (1) CA2972846A1 (de)
WO (1) WO2016112245A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109401971B (zh) * 2018-12-28 2024-01-30 江苏省人民医院（南京医科大学第一附属医院） 一种多功能自动化独立/联合共培养装置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US20040259177A1 (en) * 2003-05-06 2004-12-23 Lowery Robert G. Three dimensional cell cultures in a microscale fluid handling system
WO2008060449A2 (en) * 2006-11-09 2008-05-22 President And Fellows Of Harvard College Microfluidic detector
US20110027804A1 (en) * 2008-01-10 2011-02-03 Hurel Corporation Immune system modeling devices and methods
US20140038279A1 (en) * 2011-02-28 2014-02-06 President And Fellows Of Harvard College Cell culture system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US20040259177A1 (en) * 2003-05-06 2004-12-23 Lowery Robert G. Three dimensional cell cultures in a microscale fluid handling system
WO2008060449A2 (en) * 2006-11-09 2008-05-22 President And Fellows Of Harvard College Microfluidic detector
US20110027804A1 (en) * 2008-01-10 2011-02-03 Hurel Corporation Immune system modeling devices and methods
US20140038279A1 (en) * 2011-02-28 2014-02-06 President And Fellows Of Harvard College Cell culture system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARLENS STEFAN ET AL: "Ex vivo T lymphocyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution", EXPERIMENTAL HEMATO, ELSEVIER INC, US, vol. 28, no. 10, 1 October 2000 (2000-10-01), pages 1137 - 1146, XP009165868, ISSN: 0301-472X, DOI: 10.1016/S0301-472X(00)00526-9 *
DMITRY SAMSONOV ET AL: "Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro", TRANSPLANTATION RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. 1, 24 April 2012 (2012-04-24), pages 4, XP021124468, ISSN: 2047-1440, DOI: 10.1186/2047-1440-1-4 *
See also references of WO2016112245A1 *
STYBAYEVA G ET AL: "Micropatterned co-cultures of T-lymphocytes and epithelial cells as a model of mucosal immune system", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 380, no. 3, 13 March 2009 (2009-03-13), pages 575 - 580, XP026422257, ISSN: 0006-291X, [retrieved on 20090131], DOI: 10.1016/J.BBRC.2009.01.164 *
VÉRONIQUE LECAULT ET AL: "Microfluidic cell culture arrays for clonal expansion and characterization of mammalian cells", 1 January 2012 (2012-01-01), XP055487736, Retrieved from the Internet <URL:http://dataaccess-p.internal.epo.org/dal/data/documents/nonpatent> *

Also Published As

Publication number Publication date
CA2972846A1 (en) 2016-07-14
EP3242671A1 (de) 2017-11-15
WO2016112245A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
IL261568B (en) Methods and compounds for RNA-directed target DNA modification and RNA-directed transcriptional regulation
EP3350313A4 (de) Ableitung von leberorganoiden aus menschlichen pluripotenten stammzellen
EP3122181A4 (de) Zusammensetzungen und verfahren zur ex-vivo-vermehrung von menschlichen hämatopoietischen stamm-/vorläuferzellen
EP3212770A4 (de) Verfahren zur effizienten verabreichung von therapeutischen molekülen in vitro und in vivo
EP3388512A4 (de) Verfahren zur trennung und kultivierung mesenchymaler stammzellen aus wharton-sulze der nabelschnur
EP3166522A4 (de) Knochenimplantat und einsetzvorrichtung
EP3169373A4 (de) Haftzusammensetzung für biologisches gewebe und verfahren zur herstellung davon
EP3044333A4 (de) Verfahren und systeme zur analyse einer organtransplantation
EP3328455A4 (de) Herstellung eines azellulären knorpeltransplantats und verwendungen davon
EP3177924A4 (de) Stabilisierung von vollblutproben
EP3274079A4 (de) Künstliche plazenta und verfahren zur herstellung
EP3352771A4 (de) Nabelschnurgewebezusammensetzungen und verfahren zur verwendung
EP3219320A4 (de) Verfahren und lösung zur kryokonservierung von nabelschnurblut und peripherem blut
EP3102251A4 (de) Knochentransplantate und verfahren zur herstellung und verwendung von knochentransplantaten
EP3376862A4 (de) Kryokonservierungszusammensetzungen und verfahren zur verwendung davon
EP3242671A4 (de) Ex vivo-verfahren zur minimierung der risiken und maximierung der vorteile von allogener blut- und knochenmarktransplantation
EP3222298A4 (de) Organ für eine transplantation und organstruktur
EP3188796A4 (de) Photosynthetische zellstoffe und verfahren zur verwendung davon
EP3143140A4 (de) Zusammensetzungen und verfahren zur einzelmolekülkonstruktion von dna
EP3131401A4 (de) Systeme und verfahren zur verbesserung der organ- oder gewebefunktion und organ- oder gewebetransplantatlanglebigkeit
EP3367975A4 (de) Zusammensetzungen und verfahren zur regeneration von knochengewebe
HK1217911A1 (zh) 自體骨髓源性幹細胞的快速輸注
EP3363288A4 (de) Zusammensetzung zur zerstörung von mikroalgen oder sphaerocarpus
EP3148522A4 (de) Neuartige verbindungen als träger hämatopoetischer stammzellen und roter blutkörperchen
EP3104902A4 (de) Knochentransplantate und verfahren zur herstellung und verwendung von knochentransplantaten

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180705

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101AFI20180629BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246665

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HACKENSACK UNIVERSITY MEDICAL CENTER

Owner name: THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0035170000

Ipc: G01N0033500000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101ALI20230404BHEP

Ipc: G01N 33/50 20060101AFI20230404BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230613

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231024